Placebo-Induced Improvements: How Therapeutic Rituals Affect the Patient's Brain

JAMS Journal of Acupuncture and Meridian Studies

Volumn 5, Issue 3, 2012, Pages 97-103

  Benedetti, Fabrizio ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b National Institute of Neuroscience Italy   (Italy)

Author keywords

Clinical trials; Conditioning; Expectation; Medical practice; Nocebo; Placebo

Indexed keywords

CANNABINOID; CHOLECYSTOKININ; OPIATE;

BASAL GANGLION; BIOCHEMISTRY; CLINICAL PRACTICE; CLINICAL TRIAL; CORPUS STRIATUM; DEPRESSION; DOPAMINERGIC ACTIVITY; DRUG DEPENDENCE; HUMAN; NERVE CELL NETWORK; NEUROANATOMY; NEUROBIOLOGY; NEUROPHYSIOLOGY; PAIN; PARKINSON DISEASE; PLACEBO EFFECT; PRIORITY JOURNAL; REVIEW; RITUAL; TREATMENT OUTCOME;

EID: 84861975428     PISSN: 20052901     EISSN: 20938152     Source Type: Journal    
DOI: 10.1016/j.jams.2012.03.001     Document Type: Review

References (60)

1. Colloca L., Benedetti F. Placebos and painkillers: is mind as really as matter?. Nature Rev Neurosci 2005, 6:545-552.
2. Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 2008, 48:33-60.
3. Benedetti F. The Patient's Brain: The Neuroscience Behind the Doctor-Patient Relationship 2010, Oxford University Press, Oxford.
4. Moerman D.E. Meaning, Medicine and the Placebo Effect 2002, Cambridge University Press, Cambridge.
5. Benedetti F., Lanotte M., Lopiano L., Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 2007, 147:260-271.
6. Wikramasekera I. A conditioned response model of the placebo effect: predictions of the model. Placebo: Theory, Research and Mechanisms 1985, Guilford Press, New York. L. White, B. Tursky, G.E. Schwartz (Eds.).
7. Siegel S. Explanatory mechanisms for placebo effects: pavlovian conditioning. The Science of the Placebo: Toward an Interdisciplinary Research Agenda 2002, BMJ Books, London. H.A. Guess, A. Kleinman, J.W. Kusek, L.W. Engel (Eds.).
8. Ader R. The role of conditioning in pharmacotherapy. The Placebo Effect: An Interdisciplinary Exploration 1997, Harvard University Press, Cambridge, MA. A. Harrington (Ed.).
9. Voudouris N.J., Peck C.L., Coleman G. The role of conditioning and verbal expectancy in the placebo response. Pain 1990, 43:121-128.
10. Price D.D., Milling L.S., Kirsch I., Duff A., Montgomery G.H., Nicholls S.S. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 1999, 83:147-156.
11. Pollo A., Amanzio M., Arslanian A., Casadio C., Maggi G., Benedetti F. Response expectancies in placebo analgesia and their clinical relevance. Pain 2001, 93:77-83.
12. Price D.D., Finniss D.G., Benedetti F. A comprehensive review of the placebo effects: recent advances and current thought. Annu Rev Psychol 2008, 59:565-590.
13. Vase L., Robinson M.E., Verne G.N., Price D.D. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005, 115:338-347.
14. Lidstone S.C., Stoessl A.J. Understanding the placebo effect: contributions from neuroimaging. Mol Imaging Biol 2007, 9:176-185.
15. Benedetti F., Carlino E., Pollo A. How placebos change the patient's brain. Neuropsychopharmacology Rev 2011, 36:339-354.
16. Benedetti F., Amanzio M., Rosato R., Blanchard C. Non-opioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nature Med 2011, 17:1228-1230.
17. Petrovic P., Kalso E., Petersson K.M., Ingvar M. Placebo and opioid analgesia - imaging a shared neuronal network. Science 2002, 295:1737-1740.
18. Eippert F., Bingel U., Schoell E.D., Yacubian J., Klinger R., Lorenz J., et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 2009, 63:533-543.
19. Zubieta J.K., Stohler C.S. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci 2009, 1156:198-210.
20. Petrovic P., Dietrich T., Fransson P., Andersson J., Carlsson K., Ingvar M. Placebo in emotional processing-induced expectations of anxiety relief activate a generalized modulatory network. Neuron 2005, 46:957-969.
21. Kong J., Kaptchuk T.J., Polich G., Kirsch I., Vangel M., Zyloney C., et al. An fMRI study on the interaction and dissociation between expectation of pain relief and acupuncture treatment. Neuroimage 2009, 47:1066-1076.
22. Kong J., Kaptchuk T.J., Polich G., Kirsch I., Vangel M., Zyloney C., et al. Expectancy and treatment interactions: a dissociation between acupuncture analgesia and expectancy evoked placebo analgesia. Neuroimage 2009, 45:940-949.
23. Lieberman M.D., Jarcho J.M., Berman S., Naliboff B.D., Suyenobu B.Y., Mandelkern M., et al. The neural correlates of placebo effects: a disruption account. Neuroimage 2004, 22:447-455.
24. Wager T.D., Rilling J.K., Smith E.E., Sokolik A., Casey K.L., Davidson R.J., et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 2004, 303:1162-1167.
25. Ochsner K.N., Bunge S.A., Gross J.J., Gabrieli J.D. Rethinking feelings: an FMRI study of the cognitive regulation of emotion. J Cogn Neurosci 2002, 14:1215-1229.
26. Kong J., Gollub R.L., Polich G., Kirsch I., Laviolette P., Vangel M., et al. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J Neurosci 2008, 28:13354-13362.
27. de la Fuente-Fernández R., Ruth T.J., Sossi V., Schulzer M., Calne D.B., Stoessl A.J. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001, 293:1164-1166.
28. de la Fuente-Fernández R., Phillips A.G., Zamburlini M., Sossi V., Calne D.B., Ruth T.J., et al. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 2002, 136:359-363.
29. Strafella A.P., Ko J.H., Monchi O. Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation. Neuroimage 2006, 31:1666-1672.
30. Benedetti F., Colloca L., Torre E., Lanotte M., Melcarne A., Pesare M., et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nature Neurosci 2004, 7:587-588.
31. Benedetti F., Lanotte M., Colloca L., Ducati A., Zibetti M., Lopiano L. Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J Physiol 2009, 587:3869-3883.
32. Levy R., Dostrovsky J.O., Lang A.E., Sime E., Hutchison W.D., Lozano A.M. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 2001, 86:249-260.
33. Stefani A., Bassi A., Mazzone P., Pierantozzi M., Gattoni G., Altibrandi M.G., et al. Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway'. Clin Neurophysiol 2002, 113:91-100.
34. Leuchter A.F., Cook I.A., Witte E.A., Morgan M., Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002, 159:122-129.
35. Leuchter A.F., Morgan M., Cook I.A., Dunkin J., Abrams M., Witte E.A. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacoloy 2004, 177:15-22.
36. Mayberg H.S., Silva J.A., Brannan S.K., Tekell J.L., Mahurin R.K., McGinnis S., et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002, 159:728-737.
37. Volkow N.D., Wang G.J., Ma Y., Fowler J.S., Zhu W., Maynard L., et al. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 2003, 23:11461-11468.
38. Volkow N.D., Wang G.J., Ma Y., Fowler J.S., Wong C., Jayne M., et al. Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects. Neuroimage 2006, 32:1782-1792.
39. Sherman R., Hickner J. Academic physicians use placebos in clinical practice and believe in the mind-body connection. J Gen Intern Med 2007, 23:7-10.
40. Nitzan U., Lichtenberg P. Questionnaire survey on use of placebo. BMJ 2008, 329:944-946.
41. Lichtenberg P., Heresco-Levy U., Nitzan U. The ethics of the placebo in clinical practice. J Med Ethics 2004, 30:551-554.
42. Miller F.G., Colloca L. The legitimacy of placebo treatments in clinical practice: evidence and ethics. Am J Bioethics 2009, 9:39-47.
43. Amanzio M., Pollo A., Maggi G., Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 2001, 90:205-215.
44. Miller F.G., Colloca L. The placebo effect. Illness and interpersonal healing. Perspect Biol Med 2009, 52:518-539.
45. Barrett B., Muller D., Rakel D., Rabago D., Marchand L., Scheder J. Placebo, meaning and health. J Perspect Biol Med 2006, 49:178-198.
46. Gracely R.H., Dubner R., Deeter W.D., Wolskee P.J. Clinician's expectations influence placebo analgesia. Lancet 1985, 5:43.
47. Colloca L., Lopiano L., Lanotte M., Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol 2004, 3:679-684.
48. Colloca L., Sigaudo M., Benedetti F. The role of learning in nocebo and placebo effects. Pain 2008, 136:211-218.
49. Schenk P.W. " Just breathe normally" : word choices that trigger nocebo responses in patients. Am J Nurs 2008, 108:52-57.
50. Lang E.V., Hatsiopoulou O., Koch T., Lutgendorf S., Kettenmann E., Logan H., et al. Can words hurt? Patient-provider interactions during invasive medical procedures. Pain 2005, 114:303-309.
51. Colloca L., Benedetti F. Placebo analgesia induced by social observational learning. Pain 2009, 144:28-34.
52. Bausell R.B., Lao L., Bergman S., Lee W., Berman B. Is acupuncture analgesia an expectancy effect?. Eval Health Prof 2005, 28:9-26.
53. Linde K., Witt C.M., Streng A., Weidenhammer W., Wagenpfeil S., Brinkhaus B., et al. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 2007, 128:264-271.
54. Fava M., Schoenfeld D. System and method for reducing the placebo effect in controlled clinical trials 2010, US7647235.
55. de la Cruz M., Hui D., Parsons H.A., Bruera E. Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer 2010, 116:766-774.
56. Sheftell F.D., Feleppa M., Tepper S.J., Rapoport A.M., Ciannella L., Bigal M.E. Assessment of adverse events associated with triptans. Methods of assessment influence the results. Headache 2004, 44:978-982.
57. Amanzio M., Latini Corazzini L., Vase L., Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009, 146:261-269.
58. Rief W., Nestoriuc Y., von Lilienfeld-Toal A., Dogan I., Schreiber F., Hofmann S.G., et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf 2009, 32:1041-1056.
59. Benedetti F., Carlino E., Pollo A. Hidden administration of drugs. Clin Pharmacol Ther 2011, 90:651-661.
60. Rief W., Bingel U., Schedlowski M., Enck P. Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Ther 2011, 90:722-726.